All In Biotech

NDA 217388 · Astrazeneca Ab

Wainua (Autoinjector)

Eplontersen Sodium · Subcutaneous · Transthyretin-directed RNA Interaction; Antisense Oligonucleotide

NovelOrphan

CDER novel approval, Dec 21, 2023: To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis

Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Dec 21, 2023

Approved uses

2

Original approval plus efficacy supplements

Registered trials

9

5 Phase 3, 1 recruiting

FAERS reports

175

76 serious, 16 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 15, 2026.

WAINUA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. WAINUA is a transthyretin-directed antisense oligonucleotide indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. ( 1 )

Mechanism: Eplontersen is an antisense oligonucleotide-GalNAc conjugate that causes degradation of mutant and wild-type TTR mRNA through binding to the TTR mRNA, which results in a reduction of serum TTR protein and TTR protein deposits in tissues.

Therapeutic areas: Neurology · Rare and genetic disease · Ophthalmology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 15, 2026 Supplement 5 · Efficacy OrphanLetterLabel
  • Dec 21, 2023 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelLetterReview
2 products under this application
  • WAINUA (AUTOINJECTOR) · EPLONTERSEN SODIUM EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • WAINUA · EPLONTERSEN SODIUM EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML) · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Eplontersen" as an intervention, any sponsor and status, largest first.

All 9 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death16
  • fatigue13
  • nausea13
  • neuropathy peripheral13
  • pain9
  • product dose omission issue7
  • vomiting7
  • diarrhoea6
  • hypoaesthesia6
  • pain in extremity6
  • paraesthesia6
  • vision blurred6

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202451
2025102
202622

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Wainua (Eplontersen Sodium)

2024 spending

$56.9M

Beneficiaries

251

1,331 claims

Per beneficiary

$226,539

$52,214.29 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$56,861,357

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 12 on PubMed

Sponsor: AstraZeneca · Also marketed as Wainua

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.